This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
included in the analysis, although this was not clear from the paper. The cost data used in this research were derived from a published study (Rosenheck et al. 2006 , see 'Other Publications of Related Interest' below for bibliographic details). US cost estimates were used. No price year was stated. No discounting was required as the base-case time horizon was 1 year. No discounting was reported for the secondary 5-year analysis.
Statistical analysis of costs
The costs were treated deterministically.
Indirect Costs
No productivity losses were included.
Currency
UK pounds sterling (£) and US dollars ($). The currency conversion ($ to £) was not reported.
Sensitivity analysis
Best-and worst-case scenarios were developed in order to examine different values of incidence and severity of dyskinesia, recovery and cost. There was no other examination of uncertainty for the economic analysis.
Estimated benefits used in the economic analysis
The QALY decrement per case of tardive dyskinesia and the difference were reported, but no summary measure of benefit.
Cost results
Three annualised estimates for the incremental cost of second-generation antipsychotics were considered: 
Synthesis of costs and benefits
In the base-case analysis, using the best-case scenario for second-generation antipsychotics gave an incremental costeffectiveness ratio of £26,000 ($52,000) per case of tardive dyskinesia avoided. This increased to £68,000 ($135,000) per case avoided with the higher cost estimates. The author suggested that, in the base-case, one case avoided was assumed to represent one QALY gained.
In the second analysis, the QALYs gained for a case avoided were 0.143. This produced a range of cost-effectiveness ratios from £186,335 to £482,609. Assuming a QALY gain of 0.093, the range of cost-effectiveness ratios was from $280,505 to £726,508.
It was also assumed that 15% of cases recovered and the estimated cost per QALY ranged from £330,000 ($660,000) to £855,000 ($1,700,000).
When considering a 5-year time horizon and assuming that cost-differences remained the same over the 5 years, the cost per QALY ratios ranged from of £75,000 ($149,000) to £193,000 ($386,000).
